Winning the battle, losing the war

The noncurative "curative" resection for stage i adenocarcinoma of the lung

Sudish C. Murthy, Scott I. Reznik, Ugochukwu C. Ogwudu, Carol F. Farver, Andrea Arrossi, Lillian H. Batizy, Edward R. Nowicki, Tarek M. Mekhail, David P. Mason, Thomas W. Rice, Eugene H. Blackstone

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Understanding recurrence of surgically "cured" stage I adenocarcinoma of the lung is important given expected benefits of adjuvant therapy for advanced disease. Therefore, this study characterizes cancer recurrence and its risks, assesses survival after recurrence, and contextualizes overall survival and its risks. Methods: From 1991 to 2001, 285 patients underwent resection of stage I adenocarcinoma (pathologic) of the lung. They were followed cross-sectionally for evidence of cancer recurrence (mean follow-up 7.7 ± 4.3 years). Risk factors for recurrence and all-cause mortality were sought among demographic, medical history, cancer pathology, and surgical procedure data. Results: Cancer recurred in 99 patients. Freedom from recurrence was 92%, 72%, and 57% at 1, 5, and 10 years. Two phases of risk were found: an early hazard phase and an essentially constant late phase after 5 years, with recurrences equally distributed. Early recurrence was associated with larger tumor size in patients who did not undergo mediastinal lymphadenectomy (p = 0.004). Late recurrence was more common in patients with higher pack-years of smoking (p = 0.007). Survival after recurrence was 40% and 17% at 1 and 5 years. Overall survival (65% and 40% at 5 and 10 years) depended not only on variables related to cancer recurrence, but also those of vitality (older age, pulmonary dysfunction, postpneumonectomy state). Conclusions: Stage I adenocarcinoma of the lung recurs. Identifying high-risk patients will simplify decision making for adjuvant therapy and surveillance. Thorough mediastinal lymphadenectomy dissociates tumor size as a predictor of survival and may itself provide an important survival benefit.

Original languageEnglish (US)
Pages (from-to)1067-1074
Number of pages8
JournalAnnals of Thoracic Surgery
Volume90
Issue number4
DOIs
StatePublished - Jan 1 2010

Fingerprint

Recurrence
Survival
Neoplasms
Lymph Node Excision
Adenocarcinoma of lung
Warfare
Surgical Pathology
Decision Making
Smoking
Demography
Lung
Mortality
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Winning the battle, losing the war : The noncurative "curative" resection for stage i adenocarcinoma of the lung. / Murthy, Sudish C.; Reznik, Scott I.; Ogwudu, Ugochukwu C.; Farver, Carol F.; Arrossi, Andrea; Batizy, Lillian H.; Nowicki, Edward R.; Mekhail, Tarek M.; Mason, David P.; Rice, Thomas W.; Blackstone, Eugene H.

In: Annals of Thoracic Surgery, Vol. 90, No. 4, 01.01.2010, p. 1067-1074.

Research output: Contribution to journalArticle

Murthy, SC, Reznik, SI, Ogwudu, UC, Farver, CF, Arrossi, A, Batizy, LH, Nowicki, ER, Mekhail, TM, Mason, DP, Rice, TW & Blackstone, EH 2010, 'Winning the battle, losing the war: The noncurative "curative" resection for stage i adenocarcinoma of the lung', Annals of Thoracic Surgery, vol. 90, no. 4, pp. 1067-1074. https://doi.org/10.1016/j.athoracsur.2010.04.108
Murthy, Sudish C. ; Reznik, Scott I. ; Ogwudu, Ugochukwu C. ; Farver, Carol F. ; Arrossi, Andrea ; Batizy, Lillian H. ; Nowicki, Edward R. ; Mekhail, Tarek M. ; Mason, David P. ; Rice, Thomas W. ; Blackstone, Eugene H. / Winning the battle, losing the war : The noncurative "curative" resection for stage i adenocarcinoma of the lung. In: Annals of Thoracic Surgery. 2010 ; Vol. 90, No. 4. pp. 1067-1074.
@article{9a2d859cc9de47aeb1a64bea072f0eee,
title = "Winning the battle, losing the war: The noncurative {"}curative{"} resection for stage i adenocarcinoma of the lung",
abstract = "Background: Understanding recurrence of surgically {"}cured{"} stage I adenocarcinoma of the lung is important given expected benefits of adjuvant therapy for advanced disease. Therefore, this study characterizes cancer recurrence and its risks, assesses survival after recurrence, and contextualizes overall survival and its risks. Methods: From 1991 to 2001, 285 patients underwent resection of stage I adenocarcinoma (pathologic) of the lung. They were followed cross-sectionally for evidence of cancer recurrence (mean follow-up 7.7 ± 4.3 years). Risk factors for recurrence and all-cause mortality were sought among demographic, medical history, cancer pathology, and surgical procedure data. Results: Cancer recurred in 99 patients. Freedom from recurrence was 92{\%}, 72{\%}, and 57{\%} at 1, 5, and 10 years. Two phases of risk were found: an early hazard phase and an essentially constant late phase after 5 years, with recurrences equally distributed. Early recurrence was associated with larger tumor size in patients who did not undergo mediastinal lymphadenectomy (p = 0.004). Late recurrence was more common in patients with higher pack-years of smoking (p = 0.007). Survival after recurrence was 40{\%} and 17{\%} at 1 and 5 years. Overall survival (65{\%} and 40{\%} at 5 and 10 years) depended not only on variables related to cancer recurrence, but also those of vitality (older age, pulmonary dysfunction, postpneumonectomy state). Conclusions: Stage I adenocarcinoma of the lung recurs. Identifying high-risk patients will simplify decision making for adjuvant therapy and surveillance. Thorough mediastinal lymphadenectomy dissociates tumor size as a predictor of survival and may itself provide an important survival benefit.",
author = "Murthy, {Sudish C.} and Reznik, {Scott I.} and Ogwudu, {Ugochukwu C.} and Farver, {Carol F.} and Andrea Arrossi and Batizy, {Lillian H.} and Nowicki, {Edward R.} and Mekhail, {Tarek M.} and Mason, {David P.} and Rice, {Thomas W.} and Blackstone, {Eugene H.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/j.athoracsur.2010.04.108",
language = "English (US)",
volume = "90",
pages = "1067--1074",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Winning the battle, losing the war

T2 - The noncurative "curative" resection for stage i adenocarcinoma of the lung

AU - Murthy, Sudish C.

AU - Reznik, Scott I.

AU - Ogwudu, Ugochukwu C.

AU - Farver, Carol F.

AU - Arrossi, Andrea

AU - Batizy, Lillian H.

AU - Nowicki, Edward R.

AU - Mekhail, Tarek M.

AU - Mason, David P.

AU - Rice, Thomas W.

AU - Blackstone, Eugene H.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background: Understanding recurrence of surgically "cured" stage I adenocarcinoma of the lung is important given expected benefits of adjuvant therapy for advanced disease. Therefore, this study characterizes cancer recurrence and its risks, assesses survival after recurrence, and contextualizes overall survival and its risks. Methods: From 1991 to 2001, 285 patients underwent resection of stage I adenocarcinoma (pathologic) of the lung. They were followed cross-sectionally for evidence of cancer recurrence (mean follow-up 7.7 ± 4.3 years). Risk factors for recurrence and all-cause mortality were sought among demographic, medical history, cancer pathology, and surgical procedure data. Results: Cancer recurred in 99 patients. Freedom from recurrence was 92%, 72%, and 57% at 1, 5, and 10 years. Two phases of risk were found: an early hazard phase and an essentially constant late phase after 5 years, with recurrences equally distributed. Early recurrence was associated with larger tumor size in patients who did not undergo mediastinal lymphadenectomy (p = 0.004). Late recurrence was more common in patients with higher pack-years of smoking (p = 0.007). Survival after recurrence was 40% and 17% at 1 and 5 years. Overall survival (65% and 40% at 5 and 10 years) depended not only on variables related to cancer recurrence, but also those of vitality (older age, pulmonary dysfunction, postpneumonectomy state). Conclusions: Stage I adenocarcinoma of the lung recurs. Identifying high-risk patients will simplify decision making for adjuvant therapy and surveillance. Thorough mediastinal lymphadenectomy dissociates tumor size as a predictor of survival and may itself provide an important survival benefit.

AB - Background: Understanding recurrence of surgically "cured" stage I adenocarcinoma of the lung is important given expected benefits of adjuvant therapy for advanced disease. Therefore, this study characterizes cancer recurrence and its risks, assesses survival after recurrence, and contextualizes overall survival and its risks. Methods: From 1991 to 2001, 285 patients underwent resection of stage I adenocarcinoma (pathologic) of the lung. They were followed cross-sectionally for evidence of cancer recurrence (mean follow-up 7.7 ± 4.3 years). Risk factors for recurrence and all-cause mortality were sought among demographic, medical history, cancer pathology, and surgical procedure data. Results: Cancer recurred in 99 patients. Freedom from recurrence was 92%, 72%, and 57% at 1, 5, and 10 years. Two phases of risk were found: an early hazard phase and an essentially constant late phase after 5 years, with recurrences equally distributed. Early recurrence was associated with larger tumor size in patients who did not undergo mediastinal lymphadenectomy (p = 0.004). Late recurrence was more common in patients with higher pack-years of smoking (p = 0.007). Survival after recurrence was 40% and 17% at 1 and 5 years. Overall survival (65% and 40% at 5 and 10 years) depended not only on variables related to cancer recurrence, but also those of vitality (older age, pulmonary dysfunction, postpneumonectomy state). Conclusions: Stage I adenocarcinoma of the lung recurs. Identifying high-risk patients will simplify decision making for adjuvant therapy and surveillance. Thorough mediastinal lymphadenectomy dissociates tumor size as a predictor of survival and may itself provide an important survival benefit.

UR - http://www.scopus.com/inward/record.url?scp=77957168962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957168962&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2010.04.108

DO - 10.1016/j.athoracsur.2010.04.108

M3 - Article

VL - 90

SP - 1067

EP - 1074

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 4

ER -